Rosaceiform	rosaceiform	O	O	O	O
dermatitis	dermatitis	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
topical	topical	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
describe	describe	O	O	O	O
herein	herein	O	O	O	O
3	3	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
rosacea-like	rosacea-like	O	O	O	O
dermatitis	dermatitis	O	DISEASE	OTHERS	I
eruptions	eruptions	O	O	OTHERS	I
while	while	O	O	O	O
using	using	O	O	O	O
0.03	0.03	O	O	O	O
%	%	O	O	O	O
or	or	O	O	O	O
0.1	0.1	O	O	O	O
%	%	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
ointment	ointment	O	O	O	O
for	for	O	O	O	O
facial	facial	O	O	OTHERS	I
dermatitis	dermatitis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Skin	skin	O	O	O	O
biopsy	biopsy	O	O	O	O
specimens	specimens	O	O	O	O
showed	showed	O	O	O	O
telangiectasia	telangiectasia	O	O	OTHERS	I
and	and	O	O	O	O
noncaseating	noncaseating	O	O	O	O
epithelioid	epithelioid	O	O	O	O
granulomatous	granulomatous	O	O	O	O
tissue	tissue	O	O	O	O
formation	formation	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
papillary	papillary	O	O	O	O
to	to	O	O	O	O
mid	mid	O	O	O	O
dermis	dermis	O	O	O	O
.	.	O	O	O	O

Continuous	continuous	O	O	O	O
topical	topical	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
immunomodulators	immunomodulators	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
pimecrolimus	pimecrolimus	O	O	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
regarded	regarded	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
potential	potential	O	O	O	O
cause	cause	O	O	O	O
of	of	O	O	O	O
rosaceiform	rosaceiform	O	O	O	O
dermatitis	dermatitis	O	DISEASE	OTHERS	I
,	,	O	O	O	O
although	although	O	O	O	O
many	many	O	O	O	O
cases	cases	O	O	O	O
have	have	O	O	O	O
not	not	O	O	O	O
been	been	O	O	O	O
reported	reported	O	O	O	O
.	.	O	O	O	O

